Vistagen Therapeutics Shares Are Falling Sharply: Here's Why

Vistagen Therapeutics Inc VTGN shares are trading lower by 7.57% to $0.16 Tuesday morning after Maxim Group downgraded the stock from Buy to Hold.

What Else?

VistaGen Therapeutics shares were also trading lower during last Friday's trading session after the company announced the results from its PALISADE-1 Phase 3 clinical trial of PH94B did not achieve the primary endpoint.

PH94B did not achieve its primary endpoint, as measured by change from baseline using the Subjective Units of Distress Scale (SUDS) compared to placebo. The SUDS rating scale is used to measure the intensity of distress or nervousness in people with social anxiety... Read More

According to data from Benzinga Pro, Vistagen Therapeutics has a 52-week high of $3.26 and a 52-week low of $0.14.